Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients

Efficacy and Safety Phase Ib Study of Recombinant Human Serum Albumin/ Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Patients

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03246009

Enrollment

Registered

2017-08-10

Start date

2016-01-21

Completion date

2017-04-10

Last updated

2017-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Breast, Chemotherapy-induced Neutropenia

Keywords

Neutropenia, Chemotherapy, rHSA/GCSF

Brief summary

The purpose of this study is to evaluate the tolerance and safety of the rHSA/GCSF in breast cancer patients with different doses and multiple injections. To observe the pharmacokinetic characteristics of recombinant human serum albumin /granulocyte colony-stimulating factor fusion protein after single and multiple administration

Detailed description

This experiment adopts the method of multicenter, open, dose escalation study injection with recombinant human blood clean protein/granulocyte stimulating factor fusion protein after single and multiple doses of tolerance, security, and pharmacokinetic characteristics. Breast cancer patients with reduced white blood cells after chemotherapy were selected as subjects of this study. The three research doses that were to be incremented were 1.8 mg, 2.1mg and 2.4mg respectively, each of which was studied by single and multiple doses. Single dose of medicine, dose-climbing study.Two doses of the drug, dose-climbing study

Interventions

DRUGrHSA/GCSF

single injection-1.8mg

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Age 18-65. * Diagnosed breast cancer，received chemotherapy. * ECOG performance status 0 or 1. * ANC≥1.5×10 9/L, PLT≥100×10 9/L. No bone marrow metastasis,blood coagulation function normally, no Hemorrhagic tendency. * Leukocyte reduction occurred after chemotherapy,WBC≤3.0x109/L or ANC≤1.5x109/L. * No obvious abnormal ecg examination. * Cr，TBIL, AST, ALT≤1.5×ULN，no serious underlying disease. * Signed informed consent.

Exclusion criteria

* Chemotherapy within past 4 weeks. * Uncontrolled inflammatory disease,axillary temperature≥38℃. * Merging other malignant tumor. * Pregnancy or nursing status. * Participation in another clinical trial with and investigational product within 3 months prior to study entry. * Severe diabetes mellitus, or poor blood sugar controller. * Allergic disease or allergic constitution. History of protein allergy. * History of drug addiction and alcoholism. * Hematopoietic stem cell transplantation or organ transplantation. * Received antibiotic treatment within 72 hours before chemotherapy. * Long-term use of hormones or immunosuppressive agents. * Severe mental or neurological disorders. * Chronic disease of severe cardiac, kidney and liver. * Other conditions that would be excluded from this study according to doctors'judgment.

Design outcomes

Primary

Measure	Time frame	Description
Number of adverse events	14 days	Number of participants with AE as a measure for safety and tolerability after single and multiple dose of rHSA/GCSF

Secondary

Measure	Time frame	Description
AUC	14 days	AUC after single and multiple dose of rHSA/GCSF

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026